Table 1.
Baseline clinical and laboratory characteristics of the study group.
Table 2.
Analysis of 2-∆∆Ct values of the studied microRNAs in the studied group of patients with AML.
Table 3.
Assessment of miR-34a, miR-191, miR-199a and miR-199b expression in the context of response to induction chemotherapy and selected prognostic factors.
Table 4.
Analysis of the diagnostic utility of the studied microRNAs in detecting disease remission.
Table 5.
Association between microRNA expression levels and progression-free survival (PFS) in the study group (univariate analysis).
Table 6.
Association between the expression levels of analyzed microRNAs and progression-free survival (PFS) in the study group (multivariate analysis).
Table 7.
Analysis of the association between the expression levels of the studied microRNAs and overall survival (OS) (univariate analysis).
Table 8.
Association between the expression levels of the analyzed microRNAs and overall survival (OS) in the study group (multivariate analysis).
Table 9.
Effectiveness of the model in predicting response to DAC induction therapy based on the parameters included in the model.
Fig 1.
Comparison and specificity of ROC curves for evaluated microRNAs and proposed cut-off points for the studied microRNAs in the context of predicting response to induction chemotherapy.